Gene transfer of cytoprotective and immunomodulatory molecules for prevention of cardiac allograft rejection

European Journal of Cardio-thoracic Surgery

Volumn 24, Issue 5, 2003, Pages 794-806

  Vassalli, Giuseppe ^a,b   Fleury, Sylvain ^a,b   Li, Jianping ^a   Goy, Jean Jacques ^a   Kappenberger, Lukas ^a   Von Segesser, Ludwig K ^b  

^a University of Lausanne Medical Center   (Switzerland)

^b UNIVERSITY OF LAUSANNE   (Switzerland)

Author keywords

Gene therapy; Gene transfer; Heart; Transplantation

Indexed keywords

ALTEPLASE; CD40 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; FAS ANTIGEN; HEME OXYGENASE 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; NITRIC OXIDE SYNTHASE; OLIGODEOXYNUCLEOTIDE; PROTEIN BCL X; RECOMBINANT CYTOKINE; RECOMBINANT INTERCELLULAR ADHESION MOLECULE 1; RECOMBINANT INTERLEUKIN 10; RECOMBINANT INTERLEUKIN 4; RECOMBINANT PROTEIN; RECOMBINANT TRANSFORMING GROWTH FACTOR BETA; TRANSCRIPTION FACTOR E2F;

APOPTOSIS; ARTERIOSCLEROSIS; ARTERY DISEASE; BONE MARROW CELL; CELL PROTECTION; CLINICAL TRIAL; COMA; DONOR; GENE TRANSFER; GRAFT REJECTION; GRAFT SURVIVAL; GRAFT VERSUS HOST REACTION; HEART GRAFT; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; HEART PROTECTION; HEART TRANSPLANTATION; HUMAN; IMMUNOMODULATION; LEUKEMOID REACTION; LYMPHOCYTOSIS; LYMPHOPROLIFERATIVE DISEASE; MULTIPLE ORGAN FAILURE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT STRAIN; RECIPIENT; REPERFUSION INJURY; RESPIRATORY DISTRESS; REVIEW; SIDE EFFECT;

ANIMALS; CYTOKINES; CYTOPROTECTION; FORECASTING; GENE THERAPY; GENE TRANSFER TECHNIQUES; GRAFT REJECTION; HEART TRANSPLANTATION; HUMANS;

EID: 0242352462     PISSN: 10107940     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1010-7940(03)00456-1     Document Type: Review

References (105)

1. Valantine H.A., Schroeder J.S. Recent advances in cardiac transplantation. N Engl J Med. 333:(10):1995;660-661.
2. Libby P., Tanaka H. The pathogenesis of coronary arteriosclerosis ('chronic rejection') in transplanted hearts. Clin Transplant. 8:(3 Pt 2):1994;313-318.
3. Nagano H., Tilney N.L. Chronic allograft failure: the clinical problem. Am J Med Sci. 313:(5):1997;305-309.
4. Beniaminovitz A., Itescu S., Lietz K., Donovan M., Burke E.M., Groff B.D., Edwards N., Mancini D.M. Prevention of rejection in cardiac transplantation by blockade of the interleukin-2 receptor with a monoclonal antibody. N Engl J Med. 342:(9):2000;613-619.
5. Denton M.G., Magee C.C., Sayegh M.H. Immunosuppressive strategies in transplantation. Lancet. 353:(9158):1999;1083-1091.
6. Vassalli G., Büeler H., Dudler J., von Segesser L.K., Kappenberger L. Adeno-associated virus (AAV) vectors achieve prolonged transgene expression in mouse myocardium and arteries in vivo: a comparative study with adenovirus vectors. Int J Cardiol. 90:2003;231-240.
7. Guillot C., Mathieu P., Coathalem H., Le Mauff B., Castro M.G., Tesson L., Usal C., Laumonier T., Brouard S., Soulillou J.P., Lowenstein P.R., Cuturi M.C., Anegon I. Tolerance to cardiac allografts via local and systemic mechanisms after adenovirus-mediated CTLA4Ig expression. J Immunol. 164:(10):2000;5258-5268.
8. Henry T.D., Annex B.H., McKendall G.R., Azrin M.A., Lopez J.J., Giordano F.J., Shah P.K., Willerson J.T., Benza R.L., Berman D.S., Gibson C.M., Bajamonde A., Rundle A.C., Fine J., McCluskey E.R. The VIVA trial: vascular endothelial growth factor in ischemia for vascular angiogenesis. Circulation. 107:(10):2003;1359-1365.
9. Franz W.M., Rothmann T., Frey N., Katus H.A. Analysis of tissue-specific gene delivery by recombinant adenoviruses containing cardiac-specific promoters. Cardiovasc Res. 35:(3):1997;560-566.
10. Lee J., Laks H., Drinkwater D.C., Blitz A., Lam L., Shiraishi Y., Chang P., Drake T.A., Ardehali A. Cardiac gene transfer by intracoronary infusion of adenovirus vector-mediated reporter gene in the transplanted mouse heart. J Thorac Cardiovasc Surg. 111:(1):1996;246-252.
11. Donahue J.K., Kikkawa K., Johns D.C., Marban E., Lawrence J.H. Ultrarapid, highly efficient viral gene transfer to the heart. Proc Natl Acad Sci USA. 94:(9):1997;4664-4668.
12. Lee L.Y., Patel S.R., Hackett N.R., Mack C.A., Polce D.R., El-Sawy T., Hachamovitch R., Zanzonico P., Sanborn T.A., Parikh M., Isom O.W., Crystal R.G., Rosengart T.K. Focal angiogenic therapy using intramyocardial delivery of an adenovirus vector coding for vascular endothelial growth factor 121. Ann Thorac Surg. 69:(1):2000;14-24.
13. Sen L., Hong Y.S., Luo H., Cui G., Laks H. Efficiency, efficacy, and adverse effects of adenovirus- vs. liposome-mediated gene therapy in cardiac allografts. Am J Physiol Heart Circ Physiol. 281:(3):2001;H1433-H1441.
14. Sawa Y., Suzuki K., Bai H.Z., Shirakura R., Morishita R., Kaneda Y., Matsuda H. Efficiency of in vivo gene transfection into transplanted rat heart by coronary infusion of HVJ liposome. Circulation. 92:(9 Suppl 2):1995;II479-II482.
15. Couffinhal T., Kearney M., Sullivan A., Silver M., Tsurumi Y., Isner J.M. Histochemical staining following LacZ gene transfer underestimates transfection efficiency. Hum Gene Ther. 8:(8):1997;929-934.
16. Wright M.J., Rosenthal E., Stewart L., Wightman L.M., Miller A.D., Latchman D.S., Marber M.S. β-Galactosidase staining following intracoronary infusion of cationic liposomes in the in vivo rabbit heart is produced by microinfarction rather than effective gene transfer: a cautionary tale. Gene Ther. 5:(3):1998;301-308.
17. Schulick A.H., Vassalli G., Dunn P.F., Dong G., Rade J.J., Zamarron C., Dichek D.A. Established immunity precludes adenovirus-mediated gene transfer in rat carotid arteries. Potential for immunosuppression and vector engineering to overcome barriers of immunity. J Clin Invest. 99:(2):1997;209-219.
18. Harvey B.G., Hackett N.R., El-Sawy T., Rosengart T.K., Hirschowitz E.A., Lieberman M.D., Lesser M.L., Crystal R.G. Variability of human systemic humoral immune responses to adenovirus gene transfer vectors administered to different organs. J Virol. 73:(8):1999;6729-6742.
19. Schröder G., Risch K., Nizze H., Kolls J., Reinke P., Brock J., Lehmann M., Volk H.D., Ritter T. Immune response after adenoviral gene transfer in syngeneic heart transplants: effects of anti-CD4 monoclonal antibody therapy. Transplantation. 70:(1):2000;191-198.
20. Chan S.Y., Li K., Piccotti J.R., Louie M.C., Judge T.A., Turka L.A., Eichwald E.J., Bishop D.K. Tissue-specific consequences of the anti-adenoviral immune response: implications for cardiac transplants. Nat Med. 5:(10):1999;1143-1149.
21. Larsen C.P., Morris P.J., Austyn J.M. Migration of dendritic leukocytes from cardiac allografts into host spleen: A novel pathway for initiation of rejection. J Exp Med. 171:(1):1990;307-314.
22. Chan S.Y., Goodman R.E., Szmuszkovicz J.R., Roessler B., Eichwald E.J., Bishop D.K. DNA-liposome versus adenoviral mediated gene transfer of transforming growth factor beta1 in vascularized cardiac allografts: differential sensitivity of CD4+ and CD8+ T cells to transforming growth factor beta1. Transplantation. 70:(9):2000;1292-1304.
23. Sawa Y., Suzuki K., Bai H.Z., Shirakura R., Morishita R., Kaneda Y., Matsuda H. Efficiency of in vivo gene transfection into transplanted rat heart by coronary infusion of HVJ liposome. Circulation. 92:(2):1995;479-482.
24. Madsen J.C., Superina R.A., Wood K.J., Morris P.J. Immunological unresponsiveness induced by recipient cells transfected with donor MHC genes. Nature. 332:(6160):1988;161-164.
25. Fleury S., Simeoni E., Zuppinger C., Deglon N., von Segesser L.K., Kappenberger L., Vassalli G. Multiply attenuated, self-inactivating lentiviral vectors efficiently deliver and express genes for extended periods of time in adult rat cardiomyocytes in vivo. Circulation. 2003;. 107(18):2375-82.
26. Wilhelm M.J., Pratschke J., Beato F., Taal M., Kusaka M., Hancock W.W., Tilney N.L. Activation of the heart by donor brain death accelerates acute rejection after transplantation. Circulation. 102:(19):2000;2426-2433.
27. Grinyo J.M. Reperfusion injury. Transplant Proc. 29:(1-2):1997;59-62.
28. Sakaguchi T., Sawa Y., Fukushima N., Nishimura M., Ichikawa H., Kaneda Y., Matsuda H. A novel strategy of decoy transfection against nuclear factor-kappa B in myocardial preservation. Ann Thorac Surg. 71:(2):2001;629-630.
29. Iwata A., Sai S., Nitta Y., Chen M., de Fries-Hallstrand R., Dalesandro J., Thomas R., Allen M.D. Liposome-mediated gene transfection of endothelial nitric oxide synthase reduces endothelial activation and leukocyte infiltration in transplanted hearts. Circulation. 103(22):2001;2753-2759.
30. Perdrizet G.A., Kaneko H., Buckley T.M., Fishman M.S., Pleau M., Bow L., Schweizer R.T. Heat shock and recovery protects renal allografts from warm ischemic injury and enhances HSP72 production. Transplant Proc. 25:(1 Pt 2):1993;1670-1673.
31. Jayakumar J., Suzuki K., Sammut I.A., Smolenski R.T., Khan M., Latif N., Abunasra H., Murtuza B., Amrani M., Yacoub M.H. Heat shock protein 70 gene transfection protects mitochondrial and ventricular function against ischemia-reperfusion injury. Circulation. 104:(12 Suppl 1):2001;I303-I307.
32. Hancock W.W., Buelow R., Sayegh M.H., Turka L.A. Antibody-induced transplant arteriosclerosis is prevented by graft expression of anti-oxidant and anti-apoptotic genes. Nat Med. 4:(12):1998;1392-1396.
33. Magee J.C., DeBruyne L.A., Buelow R., Bromberg J.S. Gene transfer of immunosuppresive peptides B2702 and RDP1257 prolongs allograft survival: evidence suggesting a role for heme oxygenase-1. Transplant Proc. 31:(1-2):1999;1194.
34. Seder R.A., Paul W.E. Acquisition of lymphokine-producing phenotype by CD4+ T cells. Annu Rev Immunol. 12:1994;635-673.
35. Mosmann T., Sad S. The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol Today. 17:(3):1996;138-146.
36. Takeuchi T., Lowry R.P., Konieczny B. Heart allografts in murine systems: the differential activation of Th2-like effector cells in peripheral tolerance. Transplantation. 53:(6):1992;1281-1294.
37. Mottram P.L., Han W.R., Purcell L.J., McKenzie I.F., Hancock W.W. Increased expression of IL-4 and IL-10 and decreased expression of IL-2 and interferon-γ in long-surviving mouse heart allografts after brief CD-4 monoclonal antibody therapy. Transplantation. 59:(4):1995;559-565.
38. Raisanen-Sokolowski A., Glysing-Jensen T., Koglin J., Russell M.E. Reduced transplant arteriosclerosis in murine cardiac allografts placed in interferon-gamma knockout recipients. Am J Pathol. 152:(2):1998;359-365.
39. Mottram P.L., Raisanen-Sokolowski A., Glysing-Jensen T., Stein-Oakley A.N., Russell M.E. Cardiac allografts from IL-4 knockout recipients: assessment of transplant arteriosclerosis and peripheral tolerance. J Immunol. 161:(2):1998;602-609.
40. Raisanen-Sokolowski A., Glysing-Jensen T., Russell M.E. Leukocyte-suppressing influences of interleukin (IL)-10 in cardiac allografts: insights from IL-10 knockout mice. Am J Pathol. 153:(5):1998;1491-1500.
41. Koglin J., Glysing-Jensen T., Raisanen-Sokolowski A., Russell M.E. Immune sources of transforming growth factor-beta 1 reduce transplant arteriosclerosis: insights from a knockout mouse model. Circ Res. 83:(6):1998;652-660.
42. Ritter T., Schroder G., Risch K., Vergopoulos S., Shean M.K., Kolls J., Brock J., Lehmann M., Volk H.D. Ischemia/reperfusion injury-mediated down-regulation of adenovirus-mediated gene expression in a rat heart transplantation model is inhibited by co-application of a TNFRp55-Ig chimeric construct. Gene Ther. 7:(14):2000;1238-1243.
43. Suzuki K., Murtuza B., Smolenski R.T., Sammut I.A., Suzuki N., Kaneda Y., Yacoub M.H. Overexpression of interleukin-1 receptor antagonist provides cardioprotection against ischemia-reperfusion injury associated with reduction in apoptosis. Circulation. 104:(Suppl 1):2001;I308-I313.
44. Li J., Fleury S., Simeoni E., von Segesser L.K., Kappenberger L., Vassalli G. Ex vivo gene transfer of cytokine and chemokine receptor antagonists prolongs cardiac allograft survival in a rat model of heart transplantation. Eur Heart J. 2003;. (abstract book: 3259).
45. Jovanovic D.V., Di Battista J.A., Martel-Pelletier J., Jolicoeur F.C., He Y., Zhang M., Mineau F., Pelletier J.P. IL-17 stimulates the production and expression of proinflammatory cytokines, IL-1β and TNF-α, by human macrophages. J Immunol. 160:(7):1998;3513-3521.
46. Antonysamy M.A., Fanslow W.C., Fu F., Li W., Qian S., Troutt A.B., Thomson A.W. Evidence for a role of IL-17 in organ allograft rejection: IL-17 promotes the functional differentiation of dendritic cell progenitors. J Immunol. 162:(1):1999;577-584.
47. Dinarello C.A. Targeting interleukin 18 with interleukin 18 binding protein. Ann Rheum Dis. 59:(Suppl 1):2000;i17-i20.
48. Brauner R., Nonoyama M., Laks H., Drinkwater D.C. Jr, McCaffery S., Drake T., Berk A.J., Sen L., Wu L. Intracoronary adenovirus-mediated transfer of immunosuppressive cytokine genes prolongs allograft survival. J Thorac Cardiovasc Surg. 114:(6):1997;923-933.
49. David A., Chetritt J., Guillot C., Tesson L., Heslan J.M., Cuturi M.C., Soulillou J.P., Anegon I. Interleukin-10 produced by recombinant adenovirus prolongs survival of cardiac allografts in rats. Gene Ther. 7:(6):2000;505-510.
50. Zuo Z., Wang C., Carpenter D., Okada Y., Nicolaidou E., Toyoda M., Trento A., Jordan S.C. Prolongation of allograft survival with viral IL-10 transfection in a highly histoincompatible model of rat heart allograft rejection. Transplantation. 71:(5):2001;686-691.
51. Oshima K., Sen L., Cui G., Tung T., Sacks B.M., Arellano-Kruse A., Laks H. Localized interleukin-10 gene transfer induces apoptosis of alloreactive T cells via FAS/FASL pathway, improves function, and prolongs survival of cardiac allografts. Transplantation. 73:(7):2002;1019-1026.
52. Ke B., Ritter T., Kato H., Zhai Y., Li J., Lehmann M., Busuttil R.W., Volk H.D., Kupiec-Weglinski J.W. Regulatory cells potentiate the efficacy of IL-4 gene transfer by up-regulating Th2-dependent expression of protective molecules in the infectious tolerance pathway in transplant recipients. J Immunol. 164:(11):2000;5739-5745.
53. Qin L., Ding Y., Tahara H., Bromberg J.S. Viral IL-10-induced immunosuppression requires Th2 cytokines and impairs APC function within the allograft. J Immunol. 166(4):2001;2385-2393.
54. Ke B., Shen X.D., Zhai Y., Gao F., Busuttil R.W., Volk H.D., Kupiec-Weglinski J.W. Heme oxygenase 1 mediates the immunomodulatory and antiapoptotic effects of interleukin 13 gene therapy in vivo and in vitro. Hum Gene Ther. 13:(15):2002;1845-1857.
55. Hancock W.W., Gao W., Faia K.L., Csizmadia V. Chemokines and their receptors in allograft rejection. Curr Opin Immunol. 12:(5):2000;511-516.
56. DeBruyne L.A., Li K., Bishop D.K., Bromberg J.S. Gene transfer of virally encoded chemokine antagonists vMIP-II and MC148 prolongs cardiac allograft survival and inhibits donor-specific immunity. Gene Ther. 7:(7):2000;575-582.
57. Gong J.H., Uguccioni M.G., Dewald B., Baggiolini M., Clark-Lewis I. RANTES and MCP-3 antagonists bind multiple chemokine receptors. J Biol Chem. 271:(18):1996;10521-10527.
58. Gao W., Topham P.S., King J.A., Smiley S.T., Csizmadia V., Lu B., Gerard C.J., Hancock W.W. Targeting of the chemokine receptor CCR1 suppresses development of acute and chronic cardiac allograft rejection. J Clin Invest. 105:(1):2000;35-44.
59. Gao W., Faia K.L., Csizmadia V., Smiley S.T., Soler D., King J.A., Danoff T.M., Hancock W.W. Beneficial effects of targeting CCR5 in allograft recipients. Transplantation. 72:(7):2001;1199-1205.
60. Poston R.S., Mann M.J., Hoyt E.G., Ennen M., Dzau V.J., Robbins R.C. Antisense oligodeoxynucleotides prevent acute cardiac allograft rejection via a novel, nontoxic, highly efficient transfection method. Transplantation. 68:(6):1999;825-832.
61. Sayegh M.H., Turka L.A. The role of T-cell costimulatory activation pathways in transplant rejection. N Engl J Med. 338:(25):1998;1813-1821.
62. Guang-Lin M., Hayashi S., Yokoyama I., Namii Y., Kobayashi T., Katayama A., Nagasaka T., Hamada H., Negita M., Takagi H. Adenovirus-mediated gene transfer of CTLA4IG gene results in prolonged survival of heart allograft. Transplant Proc. 30:(7):1998;2923-2924.
63. Kita Y., Li X.K., Ohba M., Funeshima N., Enosawa S., Tamura A., Suzuki K., Amemiya H., Hayashi S., Kazui T., Suzuki S. Prolonged cardiac allograft survival in rats systemically injected with adenoviral vectors containing CTLA4Ig-gene. Transplantation. 68:(6):1999;758-766.
64. Guillot C., Guillonneau C., Mathieu P., Gerdes C.A., Menoret S., Braudeau C., Tesson L., Renaudin K., Castro M.G., Lowenstein P.R., Anegon I. Prolonged blockade of CD40-CD40 ligand interactions by gene transfer of CD40Ig results in long-term heart allograft survival and donor-specific hyporesponsiveness, but does not prevent chronic rejection. J Immunol. 168:(4):2002;1600-1609.
65. Braunberger E., Cohen J.L., Boyer O., Pegaz-Fiornet B., Raynal-Raschilas N., Bruneval P., Thomas-Vaslin V., Bellier B., Carpentier A., Glotz D., Klatzmann D. T-cell suicide gene therapy for organ transplantation: induction of long-lasting tolerance to allogeneic heart without generalized immunosuppression. Mol Ther. 2:(6):2000;596-601.
66. Bonini C., Ferrari G., Verzeletti S., Servida P., Zappone E., Ruggieri L., Ponzoni M., Rossini S., Mavilio F., Traversari C., Bordignon C. HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science. 276:(5319):1997;1719-1724.
67. Wong W., Stranford S.A., Morris P.J., Wood K.J. Retroviral gene transfer of a class I MHC gene to recipient bone marrow induces tolerance to alloantigens in vivo. Transplant Proc. 29:(1-2):1997;1130.
68. Geissler E.K., Scherer M.N., Graeb C. Soluble donor MHC class I gene transfer to thymus promotes allograft survival in a high-responder heart transplant model. Transplant Int. 13:(Suppl 1):2000;S452-S455.
69. Fry J.W., Morris P.J., Wood K.J. Adenoviral transfer of a single donor-specific MHC class I gene to recipient bone marrow cells can induce specific immunological unresponsiveness in vivo. Gene Ther. 9:(3):2002;220-226.
70. Dunn M.J., Crisp S., Rose M.L., Taylor P., Yacoub M.H. Antiendothelial antibodies and coronary artery disease after cardiac transplantation. Lancet. 339:(8809):1992;1566-1570.
71. Russell P.S., Chase C.M., Colvin R.B. Alloantibody and T cell mediated immunity in the pathogenesis of transplant arteriosclerosis. Lack of progression to sclerotic lesions in B cell deficient mice. Transplantation. 64:(11):1997;1531-1536.
72. Russell P.S., Chase C.M., Colvin R.B. Contributions of cellular and humoral immunity to arteriopathic lesions in transplanted mouse hearts. Transplant Proc. 29:(6):1997;2527-2528.
73. Russell P.S., Chase C.M., Sykes M., Ito H., Shaffer J., Colvin R.B. Tolerance, mixed chimerism, and chronic transplant arteriopathy. J Immunol. 167:(10):2001;5731-5740.
74. Opelz G. Critical evaluation of the association of acute with chronic graft rejection in kidney and heart transplant recipients. The Collaborative Transplant Study. Transplant Proc. 29:(1-2):1997;73-76.
75. Costanzo-Nordin M.R. Cardiac allograft vasculopathy: relationship with acute cellular rejection and histocompatibility. J Heart Lung Transplant. 11:(3 Pt 2):1992;S90-103.
76. Mathieu P., Mathieu P., Guillot C., Gerdes C., Buzelin F., Lowenstein P., Castro M., Soulillou J.P., Anegon I. Adenovirus-mediated CD40Ig expression attenuates chronic vascular rejection lesions in an aorta allotransplantation model. Transplant Proc. 34:(3):2002;743-744.
77. Shimizu K., Schonbeck U., Mach F., Libby P., Mitchell R.N. Host CD40 ligand deficiency induces long-term allograft survival and donor-specific tolerance in mouse cardiac transplantation but does not prevent graft arteriosclerosis. J Immunol. 165:(6):2000;3506-3518.
78. Wang T., Dong C., Stevenson S.C., Herderick E.E., Marshall-Neff J., Vasudevan S.S., Moldovan N.I., Michler R.E., Movva N.R., Goldschmidt-Clermont P.J. Overexpression of soluble fas attenuates transplant arteriosclerosis in rat aortic allografts. Circulation. 106:(12):2002;1536-1542.
79. Bouche D., Chauveau C., Roussel J.C., Mathieu P., Braudeau C., Tesson L., Soulillou J.P., Iyer S., Buelow R., Anegon I. Inhibition of graft arteriosclerosis development in rat aortas following heme oxygenase-1 gene transfer. Transplant Immunol. 9:(2-4):2002;235-238.
80. Suzuki J., Isobe M., Morishita R., Nishikawa T., Amano J., Kaneda Y. Antisense Bcl-x oligonucleotide induces apoptosis and prevents arterial neointimal formation in murine cardiac allografts. Cardiovasc Res. 45:(3):2000;783-787.
81. Scholl F.G., Sen L., Drinkwater D.C., Laks H., Ma X.Y., Hong Y.S., Chang P., Cui G. Effects of human tissue plasminogen gene transfer on allograft coronary atherosclerosis. J Heart Lung Transplant. 20:(3):2001;322-329.
82. Kawauchi M., Suzuki J., Morishita R., Wada Y., Izawa A., Tomita N., Amano J., Kaneda Y., Ogihara T., Takamoto S., Isobe M. Gene therapy for attenuating cardiac allograft vasculopathy using ex vivo E2F decoy transfection by HVJ-AVE-liposome method in mice and nonhuman primates. Circ Res. 87:(11):2000;1063-1068.
83. Billingham R.E., Brent L., Medawar P.B. Actively acquired tolerance of foreign cells. Nature. 172:1953;603-606.
84. Salama A.D., Remuzzi G., Harmon W.E., Sayegh M.H. Challenges to achieving clinical transplantation tolerance. J Clin Invest. 108:(7):2001;943-948.
85. Burlingham W.J., Grailer A.P., Fechner J.H. Jr, Kusaka S., Trucco M., Kocova M., Belzer F.O., Sollinger H.W. Microchimerism linked to cytotoxic T lymphocyte functional unresponsiveness (clonal anergy) in a tolerant renal transplant recipient. Transplantation. 59:(8):1995;1147-1155.
86. Strober S., Benike C., Krishnaswamy S., Engleman E.G., Grumet F.C. Clinical transplantation tolerance twelve years after prospective withdrawal of immunosuppressive drugs: studies of chimerism and anti-donor reactivity. Transplantation. 69:(8):2000;1549-1554.
87. Sykes M. Mixed chimerism and transplant tolerance. Immunity. 14:(4):2001;417-424.
88. Lechler R., Ng W.F., Steinman R.M. Dendritic cells in transplantation: friend or foe? Immunity. 14:(4):2001;357-368.
89. Kirk A.D., Burkly L.C., Batty D.S., Baumgartner R.E., Berning J.D., Buchanan K., Fechner J.H. Jr, Germond R.L., Kampen R.L., Patterson N.B., Swanson S.J., Tadaki D.K., TenHoor C.N., White L., Knechtle S.J., Harlan D.M. Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primates. Nat Med. 5:(6):1999;686-693.
90. Knechtle S.J., Fechner J.H. Jr, Dong Y., Stavrou S., Neville D.M. Jr, Oberley T., Buckley P., Armstrong N., Rusterholz K., Hong X., Tsuchida M., Hamawy M.M. Primate renal transplants using immunotoxins. Surgery. 124:(2):1998;438-446.
91. Abrams J.R., Lebwohl M.G., Guzzo C.A., Jegasothy B.V., Goldfarb M.T., Goffe B.S., Menter A., Lowe N.J., Krueger G., Brown M.J., Weiner R.S., Birkhofer M.J., Warner G.L., Berry K.K., Linsley P.S., Krueger J.G., Ochs H.D., Kelley S.L., Kang S. CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris. J Clin Invest. 103:(9):1999;1243-1252.
92. Guinan E.C., Boussiotis V.A., Neuberg D., Brennan L.L., Hirano N., Nadler L.M., Gribben J.G. Transplantation of anergic histoincompatible bone marrow allografts. N Engl J Med. 340:(22):1999;1704-1714.
93. Davidson A., Diamond B. Autoimmune diseases. N Engl J Med. 345:(5):2001;340-350.
94. Wood K.J., Prior T.G. Gene therapy in transplantation. Curr Opin Mol Ther. 3:(4):2001;390-398.
95. Orloff M.S., DeMara E.M., Coppage M.L., Leong N., Fallon M.A., Sickel J., Zuo X.J., Prehn J., Jordan S.C. Prevention of chronic rejection and graft arteriosclerosis by tolerance induction. Transplantation. 59:(2):1995;282-288.
96. Madsen J.C., Yamada K., Allan J.S., Choo J.K., Erhorn A.E., Pins M.R., Vesga L., Slisz J.K., Sachs D.H. Transplantation tolerance prevents cardiac allograft vasculopathy in major histocompatibility complex class I-disparate miniature swine. Transplantation. 65:(3):1998;304-313.
97. Hamawy M.M., Knechtle S.J. Strategies for tolerance induction in nonhuman primates. Curr Opin Immunol. 10:(5):1998;513-517.
98. Blau H.M., Rossi F.M.V. Tet B or not Tet B: advances in tetracycline-inducible gene expression. Proc Natl Acad Sci USA. 96:(3):1999;797-799.
99. Weig H.J., Laugwitz K.L., Moretti A., Kronsbein K., Städele C., Brüning S., Seyfarth M., Brill T., Schömig A., Ungerer M. Enhanced cardiac contractility after gene transfer of V2 vasopressin receptors in vivo by ultrasound-guided injection or transcoronary delivery. Circulation. 101:(13):2000;1578-1585.
100. Hollon T. Researchers and regulators reflect on first gene therapy death. Nat Med. 6:(1):2000;6.
101. Schiedner G., Morral N., Parks R.J., Wu Y., Koopmans S.C., Langston C., Graham F.L., Beaudet A.L., Kochanek S. Genomic DNA transfer with a high-capacity adenovirus vector results in improved in vivo gene expression and decreased toxicity. Nat Genet. 18:(3):1998;180-183.
102. Hacein-Bey-Abina S., Le Deist F., Carlier F., Bouneaud C., Hue C., De Villartay J.P., Thrasher A.J., Wulffraat N., Sorensen R., Dupuis-Girod S., Fischer A., Davies E.G., Kuis W., Leiva L., Cavazzana-Calvo M. Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. N Engl J Med. 346:(16):2002;1185-1193.
103. Hacein-Bey-Abina S., von Kalle C., Schmidt M., Le Deist F., Wulffraat N., McIntyre E., Radford I., Villeval J.L., Fraser C.C., Cavazzana-Calvo M., Fischer A. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N Engl J Med. 348:(3):2003;255-256.
104. Verma I.M. A voluntary moratorium? Mol Ther. 7:(2):2003;141.
105. Olivares E.C., Hollis R.P., Chalberg T.W., Meuse L., Kay M.A., Calos M.P. Site-specific genomic integration produces therapeutic Factor IX levels in mice. Nat Biotechnol. 20:(11):2002;1124-1128.